Pharmacokinetic considerations in the eradication of Helicobacter pylori

Clinical Pharmacokinetics

Volumn 38, Issue 3, 2000, Pages 243-270

  Klotz, Ulrich ^a  

^a Dr Margarete F B I fur K P   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BISMUTH CITRATE; BISMUTH SALT; CARBAMAZEPINE; CLARITHROMYCIN; CYTOCHROME P450 ISOENZYME; DICLOFENAC; DIGOXIN; GLIBENCLAMIDE; KETOCONAZOLE; LANSOPRAZOLE; METOPROLOL; METRONIDAZOLE; NAPROXEN; OMEPRAZOLE; ORAL CONTRACEPTIVE AGENT; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; RANITIDINE BISMUTH CITRATE; ROXITHROMYCIN; TETRACYCLINE; THEOPHYLLINE; TINIDAZOLE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG COST; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENTERIC COATED TABLET; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; KIDNEY DISEASE; NONHUMAN; PEPTIC ULCER; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH PH;

EID: 0034061821     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200038030-00004     Document Type: Review

References (225)

1. 1. Jones DB, Howden CW, Burget DW, et al. Acid suppression in duodenal ulcer: a meta-analysis to define optimal dosing with antisecretory drugs. Gut 1987; 28: 1120-7
2. 2. Howden CW, Hunt RH. The relationship between suppression of acidity and gastric ulcer healing rates. Aliment Pharmacol Ther 1990; 4: 25-33
3. 3. Warren JR, Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; 1: 1273-5
4. 4. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med 1995; 333: 984-91
5. 5. Hopkins RJ, Girardi LS, Turney EA. Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review. Gastroenterology 1996; 110: 1244-52
6. 6. McGowan CC, Cover TL., Blaser MJ. Helicobacter pylori and gastric acid: biological and therapeutic implications. Gastroenterology 1996; 110: 926-38
7. 7. Treiber G. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 1996; 91: 246-57
8. 8. Covacci A, Telford JL, Del Giudice G, et al. Helicobacter pylori virulence and genetic geography. Science 1999; 284: 1328-33
9. 9. Blaser MJ. Ecology of Helicobacter pylori in the human stomach. J Clin Invest 1997; 100: 759-62
10. 10. Cave DR. How is Helicobacter pylori transmitted? Gastroenterology 1997; 113 Suppl. 6: S9-14
11. 11. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998; 115: 1278-82
12. 12. Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998; 115: 1272-7
13. 13. Michetti P. Vaccine against Helicobacter pylori: fact or fiction? Gut 1997; 41: 728-30
14. 14. NJH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-9
15. 15. Soll AH. Medical treatment of peptic ulcer disease: practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. JAMA 1996; 275: 622-9
16. 16. European Helicobacter Pylori Study Group. Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. Gut 1997; 41: 8-13
17. 17. Hunt RH, Lam SK. Helicobacter pylori: from art to a science. J Gastroenterol Hepatol 1998; 13: 21-8
18. 18. Peura D. Helicobacter pylori: rational management options. Am J Med 1998; 105: 424-30
19. 19. Marshall B. NSAIDs and Helicobacter pylori: therapeutic options. Lancet 1998; 352: 1001-3
20. 20. Treiber G, Ammon S, Klotz. U. 5-Day H. pylori eradication [letter]. Aliment Pharmacol Ther 1999; 13: 1252
21. 21. Xia HX, Talley NJ, Keane CT, et al. Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes. Dig Dis Sci 1997; 42: 1821-34
22. 22. Williamson R, Pipkin GA, Wood JR. New options in Helicobacter pylori eradication: efficacy, resistance and synergy. Scand J Gastroenterol 1998; 33: 36-40
23. 23 Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs 1999; 57: 905-20
24. 24. Treiber G, Klotz U. Acid secretion, response to omeprazole, and Helicobacter pylori status. Am J Gastroenterol 1997; 92: 555-6
25. 25. Verdu EF, Armstrong D, Idstrom JP, et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996; 31: 1151-6
26. 26 Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129: 1027-30
27. 27. Gillen D, Wirz AA, Ardill JE, et al. Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. Gastroenterology 1999; 116: 239-47
28. 28. Kuipers EJ, Klinkenberg-Knol EC. Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion. Gastroenterology 1999; 116: 479-83
29. 29. Treiber G, Lambert JR. The impact of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol 1998; 93: 1080-4
30. 30. Li RC, Zhu M, Schentag JJ. Achieving an optimal outcome in the treatment of infections: the role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999; 37: 1-16
31. 31. Sachs G, Meyer-Rosberg K, Scott DR, et al. Acid. protons and Helicobacter pylori. Yale J Biol Med 1996; 69: 301-16
32. +)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells. Biochem Pharmacol 1991; 42: 1875-8
33. 33. Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors - emphasis on rabeprazole. Aliment Pharmacol Ther 1999; 13 Suppl. 3: 27-36
34. 34. McTavish D, Buckley MM, Heel RC. Omeprazole: an updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs 1991; 42: 138-70
35. 35. Howden CW. Clinical pharmacology of omeprazole. Clin Pharmacokinet 1991; 20: 38-49
36. 36. Howden CW, Meredith PA, Forrest JA, et al. Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol 1984; 26: 641-3
37. 37. Andersson T, Regårdh C-G. Pharmacokinetics of omeprazole and metabolites following single intravenous and oral doses of 40 and 80mg. Drug Invest 1990; 2: 255-63
38. 38. Andersson T, Andrén K, Cederberg C, et al. Bioavailability of omeprazole as enteric coated (EC) granules in conjunction with food on the first and seventh days of treatment. Drug Invest 1990; 2: 184-8
39. 39. Andersson T, Bergstrand R, Cederberg C. Influence of acid secretory status on absorption of omeprazole from enteric coated granules. Br J Clin Pharmacol 1991; 31: 275-8
40. 40. Andersson T, Andrén K, Cederberg C, et al. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. Br J Clin Pharmacol 1990; 29: 557-63
41. 41. Andersson T, Cederberg C, Heggelund A, et al. The pharmacokinetics of single and repeated once-daily doses of 10, 20 and 40mg omeprazole as enteric-coated granules. Drug Invest 1991; 3: 45-52
42. 42. Ching MS, Mihaly GW, Angus PW, et al. Oral bioavailability of omeprazole before and after chronic therapy in patients with duodenal ulcer. Br J Clin Pharmacol 1991; 31: 166-70
43. 43. Cederberg C, Andersson T, Skanberg I. Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol 1989; 24 Suppl. 166: 33-40
44. 44. Dilger K, Zheng Z, Klotz U. Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline. Br J Clin Pharmacol 1999; 48: 438-44
45. 45. Andersson T, Regardh CG, Dahl-Puustinen ML, et al. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990; 12: 415-6
46. 46. Chiba K, Kobayashi K, Manabe K, et al. Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin-4′-hydroxylation. J Pharmacol ExpTher 1993; 266: 52-9
47. 47. Balian JD, Sukhova N, Harris JW, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995; 57: 662-9
48. 48. Andersson T, Miners JO, Veronese ME, et al. Identification of human liver cytochrome P450 isoforms mediating omeprazole metabolism. Br J Clin Pharmacol 1993; 36: 521-30
49. 49. Karam WG, Goldstein JA, Lasker JM, et al. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos 1996; 24: 1081-7
50. 50. Rost KL, Roots I. Nonlinear kinetics after high-dose omeprazole caused by saturation of genetically variable CYP2C19. Hepatology 1996; 23: 1491-7
51. 51. Yamazaki H, Inoue K, Shaw PM, et al. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 1997; 283: 434-42
52. 52. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209
53. 53. Marinac JS, Balian JD, Foxworth JW, et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther 1996; 60: 138-44
54. 54. Zhou Q. Yamamoto I, Fukuda T, et al. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. Eur J Clin Pharmacol 1999; 55: 43-7
55. 55. Sohn DR, Kobayashi K, Chiba K, et al. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992; 262: 1195-202
56. 56. Ishizaki T, Sohn DR, Kobayashi K, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994; 16: 214-5
57. 57. Caraco Y, Lagerstrom PO, Wood AJ. Ethnic and genetic determinants of omeprazole disposition and effect. Clin Pharmacol Ther 1996; 60: 157-67
58. 58. Tybring G. Bottiger Y, Widen J, et al. Enantioselective hydrox ylation of omeprazole catalyzed by CYP2C19 in Swedish white subjects. Clin Pharmacol Ther 1997; 62: 129-37
59. 59. Jacqz-Aigrain E, Bellaich M, Faure C, et al. Pharmacokinetics of intravenous omeprazole in children. Eur J Clin Pharmacol 1994; 47: 181-5
60. 60. Landahl S. Andersson T, Larsson M, et al. Pharmacokinetic study of omeprazole in elderly healthy volunteers. Clin Pharmacokinet 1992; 23: 469-76
61. 61. Howden CW, Forrest JA, Meredith PA, et al. Antisecretory effect and oral pharmacokinetics following low dose omeprazole in man. Br J Clin Pharmacol 1985; 20: 137-9
62. 14C]omeprazole in patients with impaired renal function. Clin Pharmacol Ther 1986; 40: 344-51
63. 63. Rinetti M, Regazzi MB, Villani P, et al. Pharmacokinetics of omeprazole in cirrhotic patients. Arzneimittel Forschung 1991; 41: 420-2
64. 64. Andersson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991; 21: 195-212
65. 65. Tucker GT. The interaction of proton pump inhibitors with cytochromes P450. Aliment Pharmacol Ther 1994; 8: 33-8
66. 66. Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors: focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 1996; 31: 9-28
67. 67. Dal Negro R. Pharmacokinetic drug interactions with anti-ulcer drugs. Clin Pharmacokinet 1998; 35: 135-50
68. 68. Cohen AF, Kroon R, Schoemaker HC, et al. Effects of gastric acidity on the bioavailability of digoxin: evidence for a new mechanism for interactions with omeprazole [abstract]. Br J Pharmacol 1991; 31: 565P
69. 69. Oosterhuis B, Jonkman JH, Andersson T, et al. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 1991; 32: 569-72
70. 70. Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99: 552-7
71. 71. Jaruratanasirikul S, Sriwiriyajan S. Effect of omeprazole on the pharmacokinetics of itraconazole. Eur J Clin Pharmacol 1998; 54: 159-61
72. 72. Henry DA, Somerville KW, Kitchingman G, et al. Omeprazole: effects on oxidative drug metabolism. Br J Clin Pharmacol 1984; 18: 195-200
73. 73. Sutfin T, Balmer K, Bostrom H, et al. Stereoselective interaction of omeprazole with warfarin in healthy men. Ther Drug Monit 1989; 11: 176-84
74. 74. Unge P, Svedherg LE, Nordgren A, et al. A study of the interaction of omeprazole and warfarin in anticoagulated patients. Br J Clin Pharmacol 1992; 34: 509-12
75. 75. Toon S, Holt BL, Mullins FGP, et al. Effects of cimetidine, ranitidine and omeprazole on tolbutamide pharmacokinetics. J Pharm Pharmacol 1995; 47: 85-8
76. 76. Andersson T, Bredberg E., Lagerstrom PO, et al. Lack of drug-drug interaction between three different non-steroidal anti-inflammatory drugs and omeprazole. Eur J Clin Pharmacol 1998; 54: 399-404
77. 77. Andersson T, Lagerström PO, Unge P. A study of the interaction between omeprazole and phenytoin in epileptic patients. Ther Drug Monit 1990; 12: 329-33
78. 78. Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. Br J Clin Pharmacol 1987; 24: 543-5
79. 79. Gugler R, Jensen JC. Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 1985; 89: 1235-41
80. 80. Caraco Y, Wilkinson GR, Wood AJ. Differences between white-subjects and Chinese subjects in the in vivo inhibition of cytochrome P450s 2C19, 2D6, and 3A by omeprazole. Clin Pharmacol Ther 1996; 60: 396-404
81. 81. Andersson T, Lundborg P, Regardh CG. Lack of effect of omeprazole treatment on steady-state plasma levels of metoprolol. Eur J Clin Pharmacol 1991; 40: 61-5
82. 82. Henry D, Brent P, Whyte I, et al. Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur J Clin Pharmacol 1987; 33: 369-73
83. 83. Soons PA, van den Berg G, Danhof M, et al. Influence of single-and multiple-dose omeprazole treatment on nifedipine pharmacokinetics and effects in healthy subjects. Eur J Clin Pharmacol 1992; 42: 319-24
84. 84. Naidu MUR, Shoha JC, Dixit VK, et al. Effect of multiple dose omeprazole on the pharmacokinetics of carbamazepine. Drug Invest 1994; 7: 8-12
85. 85. Blohme I, Idstrom JP, Andersson T. A study of the interaction between omeprazole and cyclosporine in renal transplant patients. Br J Clin Pharmacol 1993; 35: 156-60
86. 86. Andersson T, Andrén K, Cederberg C, et al. Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 1990; 39: 51-4
87. 87. Andersson T, Cederberg C, Edvardsson G, et al. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 1990; 47: 79-85
88. 88. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361-90
89. 89. Ito K, Iwatsubo T, Kanamitsu S, et al. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387-412
90. 90. Caraco Y, Tateishi T, Wood AJ. Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clin Pharmacol Ther 1995; 58: 62-72
91. 91. Zomorodi K, Houston JB. Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. Br J Clin Pharmacol 1996; 42: 157-62
92. 92. Diaz D. Fabre I, Daujat M, et al. Omeprazole is an aryl hydrocarbon-like inducer of human hepatic cytochrome P450. Gastroenterology 1990; 99: 737-47
93. 93. Farrell GC, Murray M. Human cytochrome P450 isoforms: their genetic heterogeneity and induction by omeprazole. Gastroenterology 1990; 99: 885-9
94. 94. Parkinson A, Hurwitz A. Omeprazole and the induction of human cytochrome P-450: a response to concerns about potential adverse effects. Gastroenterology 1991; 100: 1157-64
95. 95. Curi-Pedrosa R, Daujat M, Pichard L, et al. Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture. J Pharmacol Exp Ther 1994; 269: 384-92
96. 13C-[N-3-methyl]-caffeine breath test in poor and extensive metabolizers of S-mephenytoin. Clin Pharmacol Ther 1992; 52: 170-80
97. 97. Rost KL, Roots I. Accelerated caffeine metabolism after omeprazole treatment is indicated by urinary metabolite ratios: coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55: 402-11
98. 98. Rost KL, Brösicke H, Heinemeyer G, et al. Specific and dose-dependent enzyme induction by omeprazole in human beings. Hepatology 1994; 20: 1204-12
99. 99. Andersson T, Bergstrand R, Cederberg C, et al. Omeprazole treatment does not affect the metabolism of caffeine. Gastroenterology 1991; 101: 943-7
100. 100. Taburet AM, Geneve J, Bocquentin M, et al. Theophylline steady state pharmacokinetics is not altered by omeprazole. Eur J Clin Pharmacol 1992; 42: 343-5
101. 101. Rizzo N, Padoin C, Palombo S, et al. Omeprazole and lansoprazole are not inducers of cytochrome P4501A2 under conventional therapeutic conditions. Eur J Clin Pharmacol 1996; 49: 491-5
102. 102. Steinijans VW, Huber R, Hartmann M, et al. Lack of pantoprazole drug interactions in man: an updated review. Int J Clin Pharmacol Ther 1996; 34: 243-62
103. 103. Humphries TJ, Merritt GJ. Review article: drug interactions with agents used to treat acid-related diseases. Aliment Pharmacol Ther 1999; 13: 18-26
104. 104. Lorf T, Ramadori G, Ringe B, et al. Pantoprazole does not affect cyclosporin A blood concentrations. Eur J Clin Pharmacol 2000; 55: 733-5
105. 105. Treiber G, Walker S, Klotz U. Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate. Clin Pharmacol Ther 1994; 55: 486-91
106. 106. Goddard AF, Jessa MJ, Barrett DA, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996; 111: 358-67
107. 107. Gustavson LE, Kaiser JF, Edmonds AL, et al. Effect of omeprazole on concentrations of clarithromycin in plasma and gastric tissue at steady state. Antimicrob Agents Chemother 1995; 39: 2078-83
108. 108. Furuta T, Ohashi K, Kobayashi K, et al. Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans. Clin Pharmacol Ther 1999; 66: 265-74
109. 109. Veldhuyzen van Zanten SJ, Pollak T, Kapoor H, et al. Effect of omeprazole on movement of intravenously administered metronidazole into gastric juice and its significance in treatment of Helicobacter pylori. Dig Dis Sci 1996; 41: 1845-52
110. 110. Paulsen O, Höglund P, Walder M. No effect of omeprazole-induced hypoacidity on the bioavailability of amoxycillin or bacampicillin. Scand J Infect Dis 1989; 21: 219-23
111. 111. Treiber G, Ammon S, Klotz U. Proton-pump-inhibitor and amoxicillin interaction in vivo [abstract]. Gut 1997; 41 Suppl. 1: A91
112. 112. Pounder RE, Sharma BK, Walt RP. Twenty-four hour intragastric acidity during treatment with oral omeprazole. Scand J Gastroenterol 1986; 21 Suppl. 118: 108-17
113. 113. Lind T, Cederberg C, Ekenved G, et al. Effect of omeprazole -a gastric proton pump inhibitor - on pentagastrin stimulated acid secretion in man. Gut 1983; 24: 270-6
114. 114. Taniyama Y, Aoyama N, Kita T, et al. CYP2C19 genotype-related efficiency of omprezole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther 1999; 66: 528-34
115. 115. Sagar M, Seensalu R, Tybring G, et al. CYP2C19 genotype and phenotype determined with omeprazole in patients with acid-related disorders with and without Helicobacter pylori infection. Scand J Gastroenterol 1998; 33: 1034-8
116. 116. Labenz J, Leverkus F, Börsch G. Omeprazole plus amoxicillin for cure of Helicobacter pylori infection. Factors influencing the treatment success. Scand J Gastroenterol 1994; 29: 1070-5
117. 117. Treiber G, Ammon S, Klotz U. Age-dependent eradication of Helicobacter pylori with dual therapy. Aliment Pharmacol Ther 1997; 11: 711-8
118. 118. Barradell LB, Faulds D, McTavish D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs 1992; 44: 225-50
119. 119. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 1994; 48: 404-30
120. 120. Kroemer HK, Klotz U, Scholz M. Lansoprazol, der zweite Protonenpumpenblocker. Pharmazie 1995; 25: 44-8
121. 121. Landes BD, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet 1995; 28: 458-70
122. 122. Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs 1997; 54: 473-500
123. 123. Bergstrand R, Grind M, Nyberg G, et al. Decreased oral bioavailability of lansoprazole in healthy volunteers when given with a standardised breakfast. Clin Drug Invest 1995; 9: 67-71
124. 124. Moules I, Garrett A, Brocklebank D, et al. Gastric acid inhibition by the proton pump inhibitor lansoprazole is unaffected by food. Br J Clin Res 1993; 4: 153-61
125. 125. Gerloff J, Mignot A, Barth H, et al. Pharmacokinetics and absolute bioavailability of lansoprazole. Eur J Clin Pharmacol 1996; 50: 293-7
126. 126. Curi-Pedrosa R, Pichard L, Bonfils C, et al. Major implication of cytochrome P4503A4 in the oxidative metabolism of the antisecretory drugs omeprazole and lansoprazole in human liver microsomes and hepatocytes [abstract]. Br J Clin Pharmacol 1993; 36: 156P
127. 127. Pichard L, Curi-Pedrosa R, Bonfils C, et al. Oxidative metabolism of lansoprazole by human liver cytochromes P450. Mol Pharmacol 1995; 47: 410-8
128. 128. Pearce RE, Rodrigues AD, Goldstein JA, et al. Identification of the human P450 enzymes involved in lansoprazole metabolism. J Pharmacol Exp Ther 1996; 277: 805-16
129. 129. Sohn DR, Kwon JT, Kim HK, et al. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin Pharmacol Ther 1997; 61: 574-82
130. 130. Katsuki H, Yagi H, Arimori K, et al. Determination of R(+)-and S(-)-lansoprazole using chiral stationary-phase liquid chromatography and their enantioselective pharmacokinetics in humans. Pharm Res 1996; 13: 611-5
131. 131. Hussein Z, Granneman GR, Mukherjee D, et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol 1993; 36: 391-8
132. 132. Flouvat B, Delhotal-Landes B, Cournot A, et al. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol 1993; 36: 467-9
133. 133. Delhotal-Landes B, Flouvat B, Duchier J, et al. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol 1993; 45: 367-71
134. 134. Barclay ML, Begg EJ, Robson RA, et al. Lansoprazole pharmacokinetics differ in patients with oesophagitis compared to healthy volunteers. Aliment Pharmacol Ther 1999; 13: 1215-9
135. 135. Lefebvre RA, Flouvat B, Karolac-Tamisier S, et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther 1992; 52: 458-63
136. 136. Fuchs W. Sennewald R, Klotz U. Lansoprazole does not affect the bioavailability of oral contraceptives. Br J Clin Pharmacol 1994; 38: 376-80
137. 137. Kokufu T, Ihara N, Sugioka N, et al. Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol 1995; 48: 391-5
138. 138. Granneman GR, Karol MD, Locke CS, et al. Pharmacokinetic interaction between lansoprazole and theophylline. Ther Drug Monit 1995; 17: 460-4
139. 139. Ko JW, Jang IJ, Shin JG, et al. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers. Clin Pharmacol Ther 1999; 65: 606-14
140. 140. Andersson T, Holmberg J, Röhss K, et al. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole. Br J Clin Pharmacol 1998; 45: 369-75
141. 141. Benet LZ. Zech K. Pharmacokinetics: a relevant factor for the choice of a drug? Aliment Pharmacol Ther 1994; 8 Suppl. 1: 25-32
142. 142. Fitton A, Wiseman L. Pantoprazole: a review of its pharmacological properties and therapeutic use in acid-related disorders. Drugs 1996; 51: 460-82
143. 143. Klotz U, Kroemer HK. Pantoprazol, der dritte Protonenpumpen-inhibitor. Pharmazie 1995; 32: 24-8
144. 144. Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996; 34 Suppl. 1: S31-S50
145. 145. Pue MA, Laroche J, Meineke I, et al. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 1993; 44: 575-8
146. 146. Tanaka M, Ohkubo T, Otani K, et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4′-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997; 62: 619-28
147. 147. Gugler R, Hartmann M, Rudi J, et al. Lack of pharmacokinetic interaction of pantoprazole with diazepam in man. Br J Clin Pharmacol 1996; 42: 249-52
148. 148. Masubuchi N, Li AP, Okazaki O. An evaluation of the cytochrome P450 induction potential of pantoprazole in primary human hepatocytes. Chem Biol Interact 1998; 114: 1-13
149. 149. Hartmann M, Zech K, Bliesath H, et al. Pantoprazole lacks induction of CYP1A2 activity in man. Int J Clin Pharmacol Ther 1999; 37: 159-64
150. 150. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999; 13: 3-10
151. 151. Prakash A, Faulds D. Rabeprazole. Drugs 1998; 55: 261-7
152. 152. Swan SK, Hoyumpa AM, Merritt GJ. Review article: the pharmacokinetics of rabeprazole in health and disease. Aliment Pharmacol Ther 1999; 13: 11-7
153. 153. Langtry HD, Markham A. Rabeprazole: a review of its use in acid-related gastrointestinal disorders. Drugs 1999; 58: 725-42
154. 154. Yasuda S, Horai Y, Tomono Y, et al. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995; 58: 143-54
155. 155. Keane WF, Swan SK, Grimes I, et al. Rabeprazole: pharmacokinetics and tolerability in patients with stable, end-stage renal failure. J Clin Pharmacol 1999; 39: 927-33
156. 156. Ishizaki T, Chiba K, Manabe K, et al. Comparison of the interaction potential of a new proton pump inhibitor, E3810, versus omeprazole with diazepam in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation. Clin Pharmacol Ther 1995; 58: 155-64
157. 157. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308-12
158. 158. Grant SM, Langtry HD, Brogden RN. Ranitidine: an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases. Drugs 1989; 37: 801-70
159. 2-receptor antagonists in patients with renal insufficiency. Clin Pharmacokinet 1993; 24: 319-32
160. 160. Gladziwa U, Klotz U. Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure. Clin Pharmacokinet 1994; 27: 393-408
161. 161. Gramatté T, El Desoky E, Klotz U. Site-dependent small intestinal absorption of ranitidine. Eur J Clin Pharmacol 1994; 46: 253-9
162. 2-receptor antagonists on drug metabolism in vitro and in vivo. Pharmacol Ther 1987; 33: 157-62
163. 163. Shinn AF. Clinical relevance of cimetidine drug interactions. Drug Saf 1992; 7: 245-67
164. 164. Mitchard M, Harris A, Mullinger BM. Ranitidine drug interactions - a literature review. Pharmacol Ther 1987; 32: 293-325
165. 165. Klotz U, Kroemer HK. The drug interaction potential of ranitidine: an update. Pharmacol Ther 1991; 50: 233-44
166. 166. Wagstaff AJ. Benfield P, Monk JP. Colloidal bismuth subcitrate: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in peptic ulcer disease. Drugs 1988; 36: 132-57
167. 167. Lacey LF, Frazer NM, Keene ON, et al. Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GRI22311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). Eur J Clin Pharmacol 1994; 47: 177-80
168. 168. Koch KM, Davis IM, Gooding AE, et al. Pharmacokinetics of bismuth and ranitidine following single doses of ranitidine bismuth citrate. Br J Clin Pharmacol 1996; 42: 201-5
169. 169. Koch KM, Kerr BM, Gooding AE, et al. Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate. Br J Clin Pharmacol 1996; 42: 207-11
170. 170. Pickering LK, Feldman S, Ericsson CD, et al. Absorption of salicylate and bismuth from a bismuth subsalicylate-containing compound (Pepto-Bismol). J Pediatr 1981; 99: 654-6
171. 171. Lee SP. Studies on the absorption and excretion of tripotassium dicitrato-bismuthate in man. Res Commun Chem Pathol Pharmacol 1981; 34: 359-64
172. 172. Froomes PR, Wan AT, Keech AC, et al. Absorption and elimination of bismuth from oral doses of tripotassium dicitrato bismuthate. Eur J Clin Pharmacol 1989; 37: 533-6
173. 173. Nwokolo CU, Gavey CJ, Smith JT, et al. The absorption of bismuth from oral doses of tripotassium dicitrato bismuthate. Aliment Pharmacol Ther 1989; 3: 29-39
174. 174. Gavey CJ, Szeto ML, Nwokolo CU, et al. Bismuth accumulates in the body during treatment with tripotassium dicitrato bismuthate. Aliment Pharmacol Ther 1989; 3: 21-8
175. 175. Nwokolo CU, Lewin JF, Hudson M, et al. Transmucosal penetration of bismuth particles in the human stomach. Gastroenterology 1992; 102: 163-7
176. 176. Nwokolo CU, Prewett EJ, Sawyerr AM, et al. The effect of histamine H2-receptor blockade on bismuth absorption from three ulcer-healing compounds. Gastroenterology 1991; 101: 889-94
177. 177. Treiber G, Gladziwa U, Ittel TH, et al. Tripotassium dicitrato bismuthate: absorption and urinary excretion of bismuth in patients with normal and impaired renal function. Aliment Pharmacol Ther 1991; 5: 491-502
178. 178. Benet LZ. Safety and pharmacokinetics: colloidal bismuth subcitrate. Scand J Gastroenterol 1991; 26 Suppl. 185: 29-35
179. 179. Sjövall J, Alván G, Westerlund D. Dose-dependent absorption of amoxycillin and bacampicillin. Clin Pharmacol Ther 1985; 38: 241-50
180. 180. Paintaud G, Alvàn G, Dahl ML, et al. Nonlinearity of amoxicillin absorption kinetics in human. Eur J Clin Pharmacol 1992; 43: 283-8
181. 181. Dalhoff A, Koeppe P, von Kobyletzki D, Studies on the pharmacokinetics of amoxicillin after intravenous, intramuscular and oral administration. Arzneimittel Forschung 1981; 31: 1148-57
182. 182. Sjövall J, Westerlund D, Alvän G. Renal excretion of intrave-nously infused amoxycillin and ampicillin. Br J Clin Pharmacol 1985; 19: 191-201
183. 183. Chow MS, Route-Id RA. Pharmacokinetic data and drug monitoring: 1. Antibiotics and antiarrhythmics. J Clin Pharmacol 1975; 15: 405-18
184. 184. Ammon S, Treiber G, Kees F, et al. Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. Aliment Pharmacol Ther. In press
185. 185. Sjövall J, Alvän G, Huitfeldt B. Intra-and inter-individual vari-ation in pharmacokinetic.s of intravenously infused amoxycillin and ampicillin to elderly volunteers. Br J Clin Pharmacol 1986; 21: 171-81
186. 186. Mainz D, Borner K, Koeppe P, et al. Pharmacokinetics of lansoprazole, amoxicillin and clarithromycin when given simultaneously [abstract]. Gut 1997; 41 Suppl. 1: A96
187. 187. Shah S. Qaqish R, Patel V, et al. Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. J Pharm Pharmacol 1999; 51: 667-72
188. 188. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole. Aliment Pharmacol Ther 1999; 13: 719-29
189. 189. Peters DH, Clissold SP. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44: 117-64
190. 190. Fraschini F, Seaglione F, Demarlini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 189-204
191. 191. Markham A, McTavish D. Clarithromycin and omeprazole as Helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Drugs 1996; 51: 161-78
192. 192. Kees F, Wellenhofer M, Grobecker H. Serum and cellular pharmacokinetics of clarithromycin 500 mg q.d. and 250 mg b.i.d. in volunteers. Infection 1995; 23: 168-72
193. 193. Chu SY, Wilson DS, Guay DR, et al. Clarithromycin pharmacokinetics in healthy young and elderly volunteers. J Clin Pharmacol 1992; 32: 1045-9
194. 194. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999; 37: 385-98
195. 195. Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: interaction with P-glycoprotein. Clin Pharmacol Ther 1998; 64: 123-8
196. 196. Peters DH, Friedel HA, McTavish D. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 1992; 44: 750-99
197. 197. Lalak NJ, Morris DL. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 370-4
198. 198. Mazzei T, Surrenti C, Novelli A, et al. Pharmacokinetics of azithromycin in patients with impaired hepatic function. J Antimicrob Chemother 1993; 31 Suppl. E: 57-63
199. 199. Backman JT, Olkkola KT, Neuvonen PJ. Azithromycin does not increase plasma concentrations of oral midazolam. Int J Clin Pharmacol Ther 1995; 33: 356-9
200. 200. Yeates RA, Laufen H, Zimmermann T. Interaction between midazolam and clarithromycin: comparison with azithromycin. Int J Clin Pharmacol Ther 1996; 34: 400-5
201. 201. Young RA, Gonzalez JP, Sorkin EM. Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1989; 37: 8-41
202. 202. Markham A, Faulds D. Roxithromycin: an update of its antimicrobial activity, pharmacokinetic properties and therapeutic use. Drugs 1994; 48: 297-326
203. 203. Nilsen OG. Pharmacokinetics of macrolides: comparison of plasma, tissue and free concentrations with special reference to roxithromycin. Infection 1995; 23 Suppl. 1: S5-9
204. 204. Kees F, Holstege A, Ittner KP, et al. Pharmacokinetic interaction between proton pump inhibitors and roxithromycin in volunteers. Aliment Pharmacol Ther. In press
205. 205. Ralph ED, Clinical pharmacokinetics of metronidazole. Clin Pharmacokinet 1983; 8: 43-62
206. 206. Lau AH, Lam NP, Piscitelli SC, et al. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 1992; 23: 328-64
207. 207. Bergan T, Leinebo O, Blom-Hagen T, et al. Pharmacokinetics and bioavailability of metronidazole after tablets, suppositories and intravenous administration. Scand J Gastroenterol Suppl 1984; 19 Suppl. 91: 45-60
208. 208. Roux AF, Moirot E, Delhotal B, et al. Metronidazole kinetics in patients with acute renal failure on dialysis: a cumulative study. Clin Pharmacol Ther 1984; 36: 363-8
209. 209. Chaikin P, Alton KB, Sampson C, et al. Pharmacokinetics of tinidazole in male and female subjects. J Clin Pharmacol 1982; 22: 562-70
210. 210. Flouvat BL, Imbert C, Dubois DM, et al. Pharmacokinetics of tinidazole in chronic renal failure and in patients on haemodialysis. Br J Clin Pharmacol 1983; 15: 735-41
211. 211. Lamp KC, Freeman CD, Klutman NE, et al. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999; 36: 353-73
212. 212. Hall D, Turner P. Simultaneous pharmacokinetic analysis for comparison of absorption, distribution and elimination of some tetracycline antibiotics [abstract], Br J Clin Pharmacol 1977; 4: 638P
213. 213. Gugler R, Allgayer H. Effects of antacids on the clinical pharmacokinetics of drugs: an update. Clin Pharmacokinet 1990; 18: 210-9
214. 214. Neuvonen PJ. Interactions with the absorption of tetracyclines. Drugs 1976; 11: 45-54
215. 215. Raghuram TC, Krishnaswamy K. Pharmacokinetics of tetracycline in nutritional edema. Chemotherapy 1982; 28: 428-33
216. 216. Pagliaro LA, Benet LZ. Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references. J Pharmacokinet Biopharm 1975; 3: 333-83
217. 217. Fabre J, Milek E, Kalfopoulos P, et al. La cinétique des tétracyclines chez l'homme: II. Excrétion, pénétration dans les tissues normaux et inflammatoires, comportement en cas d'insuffisance rénale et d'hémodialyse. Schweiz Med Wochenschi 1971; 101: 625-33
218. 218. Tkach CL, Ariano RE. Significance of a tetracycline and Pepto-Bismol interaction in the management of Helicobacter pylori-induced peptic ulcer disease [letter). Ann Pharmacother 1998; 32: 387
219. 219. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection: Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. Am J Gastroenterol 1998; 93: 2330-8
220. 220. Smout AJPM. Is the sensitivity to gastric acid inhibition Helicobacter pylori status-dependent? Scand J Gastroenterol 1998; 33 Suppl. 225: 32-5
221. 221. Martinek J, Blum AL, Stolte M, et al. Effects of pumaprazole (BY84I), a novel reversible proton pump antagonist, and of omeprazole, on intragastric acidity before and after cure of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13: 27-34
222. 222. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56: 307-35
223. 223. Erah PO, Goddard AF, Barrett DA, et al. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997; 39: 5-12
224. 224. Pütsep K, Brändén CI, Boman HG, et al. Antibacterial peptide from H. pylori. Nature 1999; 398: 671-2
225. 225. Tytgat GN. Helicobacter pylori: reflections for the next millennium. Gut 1999; 45 Suppl. 1: 145-7